Gisslen M - Search Results

1

Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study.

Alagaratnam J, De Francesco D, Zetterberg H, Heslegrave A, Toombs J, Kootstra NA, Underwood J, Gisslen M, Reiss P, Fidler S, Sabin CA, Winston A. Alagaratnam J, et al. Among authors: gisslen m. J Neurovirol. 2022 Feb;28(1):54-63. doi: 10.1007/s13365-021-01026-3. Epub 2021 Dec 7. J Neurovirol. 2022. PMID: 34874540 Free PMC article.

2

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. Scand J Infect Dis. 2004;36(11-12):823-8. doi: 10.1080/00365540410025320. Scand J Infect Dis. 2004. PMID: 15764168 Clinical Trial.

3

Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.

Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, Price RW. Cinque P, et al. Among authors: gisslen m. J Neuroimmunol. 2005 Nov;168(1-2):154-63. doi: 10.1016/j.jneuroim.2005.07.002. Epub 2005 Aug 8. J Neuroimmunol. 2005. PMID: 16091292

4

Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, Gisslén M. Mellgren A, et al. Among authors: gisslen m. Antivir Ther. 2005;10(6):701-7. Antivir Ther. 2005. PMID: 16218168 Clinical Trial.

5

CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.

Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, Rosengren L, Gisslén M. Abdulle S, et al. Among authors: gisslen m. J Neurol. 2007 Aug;254(8):1026-32. doi: 10.1007/s00415-006-0481-8. Epub 2007 Apr 10. J Neurol. 2007. PMID: 17420923

6

Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.

Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Gisslen M, et al. J Infect Dis. 2007 Jun 15;195(12):1774-8. doi: 10.1086/518043. Epub 2007 May 2. J Infect Dis. 2007. PMID: 17492593

7

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers.

Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Gisslen M, et al. J Neuroimmune Pharmacol. 2007 Mar;2(1):112-9. doi: 10.1007/s11481-006-9035-1. Epub 2006 Sep 12. J Neuroimmune Pharmacol. 2007. PMID: 18040834 Review.

8

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.

Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61. doi: 10.1089/aid.2008.0216. AIDS Res Hum Retroviruses. 2009. PMID: 19320601 Free PMC article.

9

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.

Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Yilmaz A, et al. Among authors: gisslen m. PLoS One. 2009 Sep 1;4(9):e6877. doi: 10.1371/journal.pone.0006877. PLoS One. 2009. PMID: 19721718 Free PMC article.

10

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

Yilmaz A, Watson V, Else L, Gisslèn M. Yilmaz A, et al. Among authors: gisslen m. AIDS. 2009 Nov 27;23(18):2537-40. doi: 10.1097/QAD.0b013e328333ae0e. AIDS. 2009. PMID: 19855252

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page